Skip to main content

Table 1 Baseline characteristics of patients in the study and the control groups

From: Ropivacaine infiltration analgesia of the drainage exit site enhanced analgesic effects after breast Cancer surgery: a randomized controlled trial

 

Group A(n = 37)

Group B(n = 37)

P value

Age (years)a

52.1 ± 9.0

49.1 ± 9.9

0.17

Weight (kg)a

61.8 ± 8.7

59.8 ± 8.4

0.32

Height (cm)a

160.3 ± 5.5

159.4 ± 5.0

0.44

Body mass indexa

24.0 ± 3.6

23.9 ± 3.1

0.82

Smoking (%)

0

0

History of PONV (%)

5 (13.5%)

4 (10.8%)

0.48

Surgical procedure

  

0.41

 mastectomy + axillary dissection (%)

30 (80.1%)

27 (73.0%)

 

 mastectomy + SNLB (%)

7 (19.9%)

10 (27.0%)

Surgery time (min)a

98.1 ± 31.3

111.0 ± 28.8

0.07

Length of anesthesia (min)a

113.5 ± 30.1

125.5 ± 27.9

0.08

Consumption of Sufentanil (μg)a

24.8 ± 5.7

23.8 ± 5.0

0.42

  1. aValues are expressed as the mean ± standard deviation; PONV postoperative nausea and vomiting; SNLB sentinel lymph node biopsy